MARINOMED BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.5 EUR | 0.00% |
|
-3.51% | -43.49% |
| Apr. 16 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 | |
| Apr. 16 | Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company has a low valuation given the cash flows generated by its activity.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company has insufficient levels of profitability.
- With an expected P/E ratio at 53.23 and 12.6 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -43.49% | 27.63M | - | ||
| -2.32% | 92.59B | A- | ||
| +3.68% | 41.43B | A- | ||
| -11.46% | 33.49B | B- | ||
| -19.56% | 14.62B | C | ||
| -9.09% | 12.77B | B- | ||
| -11.34% | 11.58B | D+ | ||
| -43.53% | 11.35B | B | ||
| +3.75% | 8.97B | B+ | ||
| -6.32% | 8.3B | B- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MARI Stock
- Ratings Marinomed Biotech AG
